Essentially developed in triple-negative breast cancer, with promising results in both advanced and early settings35,36, recent data indicate that immune checkpoint inhibitors might be also active in ER-positive breast cancer37, thus, CINSARC could be useful to identify those Luminal B patients who could be candidate to PD1/PD-L1 targeting agents. The gene discussed is CD274; the disease is triple-negative breast carcinoma.